Bayer Settles Patent Infringement Case with Bion Tech
Bayer CropScience and Bion Tech of Taiwan, a producer of biological crop protection agents, have settled a patent infringement case in Korea.
Under the settlement, Bayer said it granted Bion Tech a royalty-bearing license to sell lipopeptide-containing products based on Bion Tech’s proprietary Bacillus subtilis Y1336 strain. Bion Tech´s strain Y1336 produces agrastatin, which is covered by claims related to lipopeptides in Bayer’s patent portfolio. These lipopeptides contribute to the unique properties of Bayer’s Serenade products, Bayer said. The license extends to various countries, with a focus on Asia. Financial terms of the settlement were not disclosed.
Mike Miille, head of business management biologics at Bayer, commented: “Biologicals play a significant role in shaping farming´s future because they help to increase yield and optimize grower´s flexibility.” He added, “Strong patent protection is the basis for this innovation.”